ECP 2022 Final Programme

Sunday, 4 Sept 166 Industry Symposia e Sunday, 4 September 2022 LS-01 Industry Symposium 13:00–14:30 Singapore Is it time to rethink HER2-expressing breast cancer? (Daiichi Sankyo and AstraZeneca) Chair: Josef Rüschoff, Germany 001 13:00–13:05 Welcome and introduction Josef Rüschoff, Germany 002 13:05–13:25 What are the challenges in scoring HER2 in breast cancer? Annette Lebeau, Germany 003 13:25–13:35 Prevalence and characteristics of breast cancers expressing low levels of HER2 Josef Rüschoff, Germany 004 13:35–13:50 Recent developments in breast cancers expressing low levels of HER2 William Jacot, France 005 13:50–14:05 What does the future hold for HER2 testing in breast cancer? Federico Rojo, Spain 006 14:05–14:25 Panel discussion and Q&A Josef Rüschoff, Germany 007 14:25–14:30 Closing Remarks Josef Rüschoff, Germany LS-02 Industry Symposium 13:00–14:30 Sydney Practical examples of precision medicine in cancer care (Janssen Pharmaceutica NV) Chairs: Eva Compérat, Austria Paul Hofman, France 001 Cancer management in the era of precision medicine Paul Hofman, France 002 Putting it into practice: A patient presenting with lung cancer Paul Hofman, France 003 Putting it into practice: A patient presenting with prostate cancer Eva Compérat, Austria 004 Putting it into practice: A patient presenting with bladder cancer Antonio Lopez-Beltran, Portugal LS-03 Industry Symposium 13:00–14:30 Montreal Onco-Pathology Forum: A Multidiscipli- nary Approach to Biomarker Diagnostics and Care (Bristol Myers Squibb) Chair: Reinhard Büttner, Germany 001 13:00–13:15 Welcome and Introduction Reinhard Büttner, Germany 002 13:15–13:25 Key Results of Immunotherapy Trials in Advanced Upper GI Tract Cancers: What Pathologists Need to Know From GI Oncology for Personalized Medicine Markus Möhler, Germany 003 13:25–13:35 Are We Ready to Move Into an Age of Biomarker-Driven Neoadjuvant Therapy in Advanced Upper GI Tract Cancers? What GI Oncologists Need to Know From a Pathology Report Thomas Zander, Germany 004 13:35–13:45 The GI Pathologist Perspective: Diagnostic Biomarkers for Advanced Upper GI Tract Cancers Alexander Quaas, Germany 005 13:45–13:55 Biomarker-Driven Therapies in Bladder Cancer: What Uro-oncologists Need to Know From a Pathology Report Juan Palou Redorta, Spain